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SUOMENKIELINEN TIIVISTELMÄ 
 
Verisuonisolujen adheesiomolekyyli 1 (VCAM-1), liukoinen Fas (sFas) ja maksasolujen 
kasvutekijä (HGF) yli 90-vuotiaiden kuolleisuuden ennustajina 
 
TAUSTA JA TAVOITTEET: Lisääntynyt solukuolema ja muutokset verisuonien endoteelin 
merkkiaineiden ja kasvutekijöiden esiintymisessä elimistössä liittyy tyypillisesti ikääntymiseen. 
Vascular cell adhesion molecule (VCAM-1), hepatocyte growth factor (HGF) ja soluble Fas (sFas) 
osallistuvat kudosten kasvun, apoptoosin ja tulehdusreaktioiden säätelyyn monissa kudoksissa. Ne 
on yhdistetty mm. sydän-ja verisuonisairauksiin ja maligniteetteihin. Me analysoimme VCAM-1-, 
HGF- ja sFas-tasojen assosiaatioita yli 90-vuotiaiden kuolleisuuteen. Tarkoituksena oli tunnistaa 
uusia merkkiaineita iäkkäiden kuolleisuuden ennustamiseksi. 
 
MENETELMÄT: Yhteensä 238:lta Tervaskanto 90+ tutkimukseen osallistuneelta henkilöltä 
määritettiin merkkiaineiden pitoisuudet plasmasta Luminex®-teknologialla. 
Merkkiainepitoisuusmääritykset yhdistettiin aiemmin kerättyihin tietoihin sairaushistoriasta ja 
kuolleisuudesta tutkimuksen nelivuotisen seuranta-ajan sisällä. Coxin suhteellisen vaaran mallia 
käytettiin näiden merkkiaineiden ja kuolleisuuden välisten assosiaatioiden analysoimiseksi. 
 
TULOKSET: Seuranta-aikana menehtyneiden henkilöiden VCAM-1, sFas ja HGF 
plasmapitoisuudet olivat suurentuneet lähtötilanteessa. Analyyseissa, joissa useita muita tunnettuja 
riskitekijöitä otettiin huomioon, nähtiin, että kuolleisuus oli suurempi henkilöillä, joilla VCAM-1 
(HR 1.85; 95% CI, 1.12-3.05) tai HGF (HR 2.22; 95% CI, 1.33-3.71) pitoisuudet olivat 
tutkimuspopulaation korkeimmassa pitoisuustertiilissä, kun heitä verrattiin matalimmassa 
pitoisuustertiilissä oleviin henkilöihin. Henkilöillä, joilla kaikki kolme merkkiainepitoisuutta olivat 
korkeimmassa tertiilissä, oli suurempi kuolleisuus, kuin niillä, joilla yhdenkään merkkiaineen 
pitoisuus ei yltänyt korkeimpaan tertiiliin (HR 3.63; 95% CI, 1.65-7.97). 
 
PÄÄTELMÄT: Tutkittujen merkkiaineiden plasmapitoisuuksien nousu erillisenä ja yhdistelminä 
on yhteydessä hyvin iäkkäiden kuolleisuuteen. 
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ABSTRACT 
 
 
BACKGROUND: Aging is characteristically accompanied by changes in vascular endothelial 
markers and growth factor as well as increased cellular death. We analysed the associations of the 
plasma levels of vascular cell adhesion molecule-1 (VCAM-1), hepatocyte growth factor (HGF) and 
soluble Fas (sFAS), and their combinations, with 4-year mortality to identify new biomarkers.  
 
METHODS: A total of 238 individuals, both community-dwelling and institutionalised, aged 89‒91 
years and participating in the Vitality 90+ study were included. Biomarkers of endothelial function 
(VCAM-1), growth factor (HGF) and a marker of apoptosis (sFAS) were determined from plasma 
using Luminex® technology. This newly-determined data was combined with earlier data e.g., 4-year 
mortality and medical history. 
 
RESULTS: Subjects who died during the follow-up had higher baseline plasma levels of VCAM-1, 
sFas, and HGF. When other known risk factors were adjusted for, subjects in the highest 
concentration tertile for VCAM-1 (HR 1.85; 95% CI, 1.12-3.05) and HGF (HR 2.22; 95% CI, 1.33-
3.71) had higher mortality compared to those in the lowest tertile. In the adjusted analyses, when 
compared to subjects with none of the biomarkers in the highest concentration tertile, mortality was 
also higher when sFas and VCAM-1 were simultaneously (HR 2.03; 95% CI, 1.13-3.64) or all three 
were simultaneously (HR 3.63; 95% CI, 1.65-7.97) in the highest concentration tertile. 
 
CONCLUSIONS: Our results suggest that increased concentrations of these biomarkers, separately 
and in combination, associate with mortality among the aged and are prognostic markers of death. 
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1 INTRODUCTION 
 
 
Aging is a complex process connected with inflammation and degenerative processes. There are 
known risk factors that predict mortality among nonagenarians ‒ for example, living in residential 
and nursing homes as well as dementia and disability (Meller ym. 1999, Nybo ym. 2003). There are 
also biomarkers eligible for predicting mortality, such as the apoliporotein E genotype (Rontu ym. 
2006), and some inflammatory markers, such as the interleukin (IL) IL-1Ra (Jylha ym. 2007) and C 
reactive protein (CRP) (Hurme ym. 2007) in nonagenarians. 
 
In our study the levels of multiple cytokines were determined using multiplex assay kits. In order to 
analyse the data we first used a stepwise Cox regression model to identify cytokines with significant 
associations with mortality. Additional Cox proportional hazards models were performed 
individually for the cytokines indicated by the stepwise model and only vascular cell adhesion 
molecule-1 (VCAM-1), soluble Fas (sFas) and hepatocyte growth factor (HGF) showed an 
association with mortality. These three markers were then selected for further analyses. IL-6 and 
tumor necrosis factor-alpha (TNF-α) were also included in the assay kits but the results on their 
association with mortality have been published previously and were therefore not included in this 
study (Jylha ym. 2007) and (Lisko ym. 2012). 
 
According to Statistics Finland, the leading cause of death in nonagenarians is cardiovascular disease. 
VCAM-1, sFas and HGF have previously been connected with generalised degeneration of the 
cardiovascular system. Higher levels of VCAM-1 have been connected to low-grade inflammation in 
atherosclerosis (Davies ym. 1993) and found to have an association with higher mortality from 
cardiovascular causes among coronary artery disease patients (Blankenberg ym. 2001). There is 
evidence suggesting that elevated serum levels of sFas are connected with cardiovascular disease 
(Nishigaki ym. 1997, Ohtsuka ym. 1999, Toyozaki ym. 1998). Cardiovascular conditions with poor 
prognoses have been associated with elevated serum levels of HGF (Lamblin ym. 2005). Although 
these biomarkers and their association with cardiovascular disease and mortality have been widely 
investigated, studies focusing on nonagenarians are scarce. Only the association of VCAM-1 with 
mortality in nonagenarians has been previously established (Huffman ym. 2011). We wanted to 
explore whether or not these three biomarkers also have an independent connection to all-cause 
mortality in nonagenarians.  
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This is the first longitudinal study in which the association between mortality and the serum levels of 
these three markers, namely VCAM-1, sFas and HGF, as well as their combinations, are studied in 
nonagenarians. Our study brings new insight into the mechanisms behind the mortality of the very 
old. As life-expectancy keeps on rising, the amount of the elderly, especially in developed countries, 
keeps on growing. This results in a shift in the population structure of multiple countries (Ezeh ym. 
2012). It is of economic and public health interest to seek new ways to keep the elderly healthy and 
keep up their quality of life. Although there is little clinical use for these cytokines at the moment, 
they might be used to guide clinical decision-making in the future.  
 
2 MATERIALS AND METHODS 
 
 
2.1 Participants and study design 
 
This study is part of the Vitality 90+, a prospective multidisciplinary population-based study of people 
aged 90 years or older in the City of Tampere in southern Finland (Jylha ja Hervonen 1999). In this 
sub-study, 535 residents of Tampere who were born between 1909 and 1910 were recruited from the 
local population register in January 2000. Both non-institutionalised and institutionalised individuals 
were included. During home visits, the participants were interviewed by study nurses, questionnaires 
were filled in with the nurses’ assistance, and blood samples were taken. The medical history of each 
participant was collected from records maintained by health care centres. According to the Population 
Register Centre, 66 of the individuals originally enrolled had died before the beginning of data 
collection, leaving 469 persons eligible for the study. An additional 42 persons died during the study 
before they were examined, while 86 persons refused to participate, mostly due to poor physical or 
mental condition, and seven could not be contacted. Another 45 persons refused blood tests and only 
took part in the interviews. Data was missing for 26 participants and, therefore, the final sample for 
the present study consisted of 263 participants who agreed to have blood tests taken and most of 
whom (90%; n =238) were also interviewed at home. A more detailed description of the study 
protocol can be found elsewhere (Jylha ym. 2007). 
 
The study protocol was approved by the Ethics Committee of the Pirkanmaa Hospital District and the 
Ethics Committee of Tampere Health Centre, and written informed consent was obtained from all 
participants.  
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2.2 Biochemical analyses 
 
The obtained fasting plasma samples were stored at -70 °C until biochemical analysis. The levels of 
total cholesterol, HDL and hs-CRP were determined using a Cobas Integra 700 automatic analyser 
with reagents and calibrators as recommended by the manufacturer (Hoffmann-La Roche Ltd., Basel, 
Switzerland). 
 
The levels of VCAM-1, ICAM-1, sFas, sFasL, MIF, tPAI-1, IL-1, IL-6, IL-8, TNF-α, MCP-1, NGF, 
insulin, HGF and leptin were determined using the commercially available multiplex assay kits 
Human sepsis/apoptosis Milliplex kit #HSEP-63K and Human Serum Adiokine Panel B #HADK-
61K-B according to the manufacturer's instructions (Millipore, United States) by using the Bio-Plex 
system (Bio-Plex 200, Bio-Rad Laboratories Inc., CA 94547, United States). Data was handled with 
Bio-Plex Manager software (Bio-Plex Manager Software 4.1, Bio-Rad Laboratories Inc., United 
States). For the cytokines selected for the final analyses the median CV% between runs was 3.3‒6.8 
for HGF, 2.5‒4.8 for VCAM-1, and 3.1‒5.0 for sFas. IL-1 and sFasL were left out of this study due 
to quality control issues. Control samples included in the kits were used as quality controls. 
 
2.3 Clinical parameters 
 
Medical diagnoses were available for 238 participants. They were collected from records maintained 
by public health care physicians, including diagnoses made in hospitals, and were coded according to 
the 10th Revision of the International Classification of Diseases (ICD-10) (Goebeler ym. 2003). Total 
cardiovascular morbidity (ICD codes I00–I99) included hypertension, coronary heart disease, chronic 
heart failure, myocardial infarction and atrial fibrillation. Infections were recorded and the infectious 
disease variable was determined to indicate a history of any infectious disease treated in a hospital, 
including gastroenteritis, erysipelas, hepatitis, pneumonia, urinary tract infections and other 
infections. This variable, therefore, measures infections at the time of the baseline examination as well 
as previous infections if severe enough to require hospitalisation. The other included diseases were 
diabetes, cancer (other than basal cell carcinoma) and dementia. In all examinations, body mass index 
(BMI) was calculated with the formula BMI = weight (kg) / height (m)2. Other covariates included 
hs-CRP, high density lipoprotein (HDL) and housing (institution vs. home). 
 
2.4 Mortality follow-up 
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Dates of death were drawn from the Population Register Centre. There were no losses to mortality 
follow-up. The follow-up time was calculated from 21 February 2000 to the date of death or to 21 
February 2004 for survivors.  
 
2.5 Statistical analysis 
 
All statistical analyses were performed with PASW Statistics 18.0. We set out to find cytokines 
associated with mortality by banding all cytokines into tertiles and using a backward stepwise Cox 
regression model to identify cytokines that had a significant effect on mortality. The cytokines 
VCAM-1, sFas, HGF, NGF, ICAM-1 and IL-8 remained in the final step of the model. Cox 
proportional hazard models were used to analyse these markers’ associations with mortality 
individually and in this analysis only VCAM-1, sFas and HGF showed a statistically significant 
association and were selected for further analysis (data not shown). 
 
Plasma levels of VCAM-1, sFas and HGF were not normally distributed. Therefore, the variables are 
reported as medians and interquartile ranges (q1‒q3) or as percentages, and the values of the 
biomarkers were divided into tertiles. The values of each marker were banded into tertiles I‒III as 
follows: <437 (I), 437–571 (II) and > 571 ng/mL (III) for VCAM-1; <6.94 (I), 6.94–8.77 (II) and 
>8.77 (III) ng/mL for sFas; and <1.05 (I), 1.05–1.97 (II) and > 1.97 (III) ng/mL for HGF. 
 
In addition, a variable with different combinations of these markers was devised. In this variable, the 
first category consists of (i) participants whose values were below the highest tertile in all of the three 
markers. The other categories ‒ (ii) the combination of both sFas and HGF in the highest tertile, (iii) 
sFas and VCAM-1 in the highest tertile, (iv) VCAM-1 and HGF in the highest tertile and (v) all three 
in the highest tertile ‒ were each compared with category (i). 
 
Differences between the groups were analysed using Pearson’s chi-square test for categorised 
variables and both the Mann–Whitney U test and Kruskal Wallis test for medians. Spearman’s 
correlation was used to analyse correlation between the plasma levels of VCAM-1, sFas and HGF. 
 
Cox proportional hazards models were used to analyse associations between the markers and all-cause 
mortality over the 4-year follow-up. The analyses were made with no adjustments (i); with adjustment 
for sex, age and living at home or in an institution (ii); and with adjustment for hs-CRP, BMI, total 
cholesterol, HDL, cardiovascular disease, dementia, cancer, history of infectious disease and diabetes 
(iii). A two-tailed p value of <0.05 was considered statistically significant. 
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3 RESULTS 
 
 
3.1 Characteristics of the Vitality 90+ Study sample 
 
The characteristics of the study population according to survival status after 4-year follow-up are 
shown in Table 1. During the 4-year follow-up, 148 (56%) participants died. Mortality was higher 
among men, institutionalised participants and those with a lower BMI or higher hs-CRP. Levels of 
VCAM-1, sFas and HGF were significantly higher in those participants who had died as compared 
to those who were still alive at follow-up. It was more common for deceased participants to have all 
three markers in the highest tertile and on the other hand survivors were more likely to have none of 
the three markers in the highest tertile. 
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In Spearman’s correlation, VCAM-1 correlated positively with sFas (r =0.16, p = 0.01) and HGF (r 
=0.16, p = 0.01). There was also a positive but not statistically significant correlation between sFas 
and HGF (r=0.11, p = 0.07). 
 
Table 2 shows the characteristics of the study population according to the tertile of the markers 
VCAM-1, sFas and HGF. Higher VCAM-1 was associated with lower total cholesterol. 
Cardiovascular disease was more common in participants in the highest VCAM-1 tertile than in those 
falling in the lowest or middle tertile. The highest and lowest tertiles of sFas had a stronger association 
with the prevalence of cardiovascular disease than the middle tertile. Furthermore, cardiovascular 
morbidity was higher in the highest and middle HGF tertile than in the lowest tertile. None of the 
three markers were associated with sex, BMI, hs-CRP, HDL, diabetes, infectious diseases, cancer, 
dementia or age. 
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3.2 Cox proportional hazards models 
 
Table 3 demonstrates the associations of the tertiles with all-cause mortality during the 4-year follow 
up. In the Cox proportional hazards model with no adjustments, the highest tertiles of all three 
markers, VCAM-1, sFas and HGF, were associated with higher mortality. The combination of sFas 
and HGF in the highest tertile was not associated with higher mortality. The combination of VCAM-
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1 and sFas in the highest tertile resulted in higher hazard ratios as did the combination of VCAM-1 
and HGF. If all three markers fell into the highest tertile, mortality was more likely.  
 
After adjustment for sex, age and home/institutional dwelling, the results remained unchanged. Even 
after further adjustment for hs-CRP, BMI, total cholesterol, HDL, cardiovascular disease, dementia, 
cancer, history of infectious disease and diabetes, the associations were only slightly altered. The 
highest tertiles of VCAM-1, HGF and both the combination of VCAM-1 and sFas as well as the 
combination of all three values in the highest tertiles were still associated with higher mortality. 
Statistical significance for the association obetween the combination of VCAM-1 and HGF in the 
highest tertile and mortality was lost after the adjustment. After the adjustments, the data indicates 
that there is also an association between the highest tertile of sFas and mortality ‒ however, the results 
were statistically borderline (p=0.06). When HGF and sFas were further adjusted for VCAM-1, the 
association of the highest tertile of HGF and mortality remained (HR 2.01; 95% CI, 1.25-3.54, p < 
0.01). sFas did not show a statistically significant association with mortality after the adjustment for 
VCAM-1. When VCAM-1 was adjusted for TNF-α, the results did not differ from those found earlier 
(data not shown). 
 
To determine whether the studied markers are also long-term indicators of mortality, deaths that 
occurred within 1 year of baseline data collection (n = 30) were excluded from the analysis. The 
results remained similar to the main analyses: the highest tertile of VCAM-1 (HR 2.20; 95% CI, 1.40‒
3.46, p < 0.01), the combination of HGF and VCAM-1 (HR 1.82; 95% CI, 1.01‒3.27, p = 0.05), the 
combination of VCAM-1 and sFas (HR 1.97; 95% CI, 1.21-3.23, p = 0.01) and the combination of 
all three markers in the highest tertile (HR 2.56; 95% CI, 1.22‒5.37, p = 0.01) were still associated 
with higher mortality. The combination of HGF and sFas in the highest tertile did not have an effect 
on mortality (HR 1.02; 95% CI, 0.47‒2.21, p = 0.96). The trends were similar in the highest tertiles 
of sFas (HR 1.34; 95% CI, 0.87‒2.06, p = 0.18) and HGF (HR 1.43; 95% CI, 0.92‒2.21, p = 0.11), 
but they were not statistically significant. 
 
Additionally, we analysed men and women separately with no adjustments. In the small 
subpopulation of men, only the highest sFas tertile was associated with higher mortality (n = 65, HR 
2.49; 95% CI, 1.23‒5.04, p = 0.01). Although statistical significance was not found, there seemed to 
be a trend of higher mortality among participants in the highest tertiles of VCAM-1 and HGF as well 
as among the participants who had the combination of sFas and HGF in the highest tertile or all three 
markers in the highest tertile. In women (n = 198), the middle (HR 1.79; 95% CI, 1.03‒3.10, p = 0.04) 
and highest (HR 3.15; 95% CI, 1.90‒5.20, p < 0.01) tertiles of VCAM-1 as well as having the 
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combination of HGF and VCAM-1 (HR 2.42; 95% CI, 1.33-4.40, p < 0.01), the combination of sFas 
and VCAM-1 (HR 2.59; 95% CI, 1.59‒4.22, p < 0.01) or all three markers (HR 3.29; 95% CI, 1.58‒
6.87, p < 0.01) in the highest tertile were associated with higher mortality. The highest tertiles of HGF 
and sFas also seemed to be associated with higher mortality, but statistical significance was not 
achieved. 
 
15 
 
 
 
As cardiovascular disease is one of the leading causes of death among the aged, we carried out 
separate analyses for different subgroups as shown in Table 4. Mortality among those with a known 
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history of cardiovascular disease (n=188) associated with the highest VCAM-1 tertile. Among those 
with no known history of cardiovascular disease, we found no statistically significant correlation 
between any of the markers and mortality. However, the size of the population is fairly small (n=50). 
In the community-dwelling group (n=238), higher mortality was associated with the highest VCAM-
1, sFas and HGF tertiles. In the very small subgroup of institutionalised participants (n = 25), the 
highest HGF tertile was associated with mortality. We were not able to carry out these separate 
analyses using the different combinations of the three markers due to the very small subgroups. 
 
 
 
4 DISCUSSION 
 
 
We found that the baseline concentrations of all three markers were significantly higher among those 
who had died during the 4-year follow-up as compared to survivors. In fact, VCAM-1 and HGF had 
a strong association with mortality even after adjustment for the major risk factors (e.g., sex, CVD, 
cancer, dementia and institutionalisation) and high levels of sFas seemed to slightly amplify the 
association of VCAM-1 and mortality. A combination of elevated levels of all three markers also 
indicated greater mortality. 
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The studied markers had only few associations with other known risk factors of cardiovascular 
disease. Although it has been previously shown that C-reactive protein causes the induction of 
VCAM-1 we did not find an association between hs-CRP levels and VCAM-1 levels (Kawanami ym. 
2006). Low VCAM-1 levels were associated with higher total cholesterol levels but HDL levels were 
not affected by VCAM-1 levels. VCAM-1 levels did not show an association with diabetes or BMI. 
sFas and HGF levels did not show any association with BMI, hs-CRP levels, total cholesterol, HDL 
or diabetes. This seems to supports our hypothesis of the markers being independent predictors of 
cardiovascular disease related mortality in nonagenarians. 
 
VCAM-1 mediates leukocyte cell adhesion and signal transduction on the endothelium (Cook-Mills 
ym. 2011). Higher levels of VCAM-1 have been connected to low-grade inflammation in 
atherosclerosis, and VCAM-1 expression is upregulated in atherosclerotic plaques (Davies ym. 1993). 
Therefore, increased plasma levels of VCAM-1 may indicate an early event in the pathogenesis of 
atherosclerosis and alternation in the functional state of endothelial cells. Higher serum levels of 
VCAM-1 have been found to be significantly related to future death from cardiovascular causes 
among coronary artery disease patients (Blankenberg ym. 2001). Some evidence also suggests that 
increased serum levels of VCAM-1 are associated with cardiovascular disease in a previously healthy 
population (Schmidt ym. 2009). However, contrary results regarding the previously healthy 
population have also been published (Malik ym. 2001). We found that participants with higher plasma 
levels of VCAM-1 did, indeed, have more cardiovascular disease than did those with lower levels at 
baseline. High levels of VCAM-1 were associated with higher mortality. The association persisted 
after adjusting for known risk factors, including cardiovascular disease, suggesting that high levels 
of VCAM-1 are predictive of higher mortality rates even in previously healthy nonagenarians. As 
VCAM-1 levels increase in inflammation, we hypothesised that nonagenarians with major 
inflammatory conditions did not survive, causing an increase in mortality. 
 
sFas is cleaved from the Fas ligand by a matrix metalloprotease. Only the membrane-bound Fas 
ligand triggers apoptosis through the Fas receptor, whereas sFas counteracts it (Lettau ym. 2011). 
Many studies have demonstrated that serum levels of sFas are elevated in patients with myocarditis, 
chronic congestive heart failure and coronary artery disease and thus indicate a possible connection 
between sFas and cardiovascular disease (Nishigaki ym. 1997, Ohtsuka ym. 1999, Toyozaki ym. 
1998). We found that participants with elevated sFas levels had more cardiovascular disease than 
those with moderate levels, which would support previous findings. Additionally we found that 
participants with low sFas levels also had more cardiovascular disease than those with moderate 
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levels. sFas levels are also elevated in neoplastic pathologies (Abbasova ym. 2009). We did not find 
a statistically significant difference in cancer prevalence as associated with sFas levels. In our 
population, higher serum levels of sFas seemed to slightly amplify the already strong association of 
high levels of VCAM-1 and mortality, but sFas did not show a statistically significant independent 
association with mortality after adjustment. We hypothesise that very low or elevated sFas levels can 
cause problems in the homeostasis between cell renewal and death. Deceased participants possibly 
had major disturbances in this delicate balance making them more susceptible to cardiovascular 
disease and less likely to survive major inflammatory conditions associated with elevated VCAM-1 
levels. 
 
HGF was originally discovered to be a mitogen for hepatocytes and a motility factor for epithelial 
cells. HGF is a heterodimeric glycoprotein of mesenchymal origin. HGF has mitogenic, antiapoptotic 
and angiogenic effects on various cell types (Maulik ym. 2002). Elevated serum levels of HGF have 
been connected with conditions with poor prognoses, such as heart failure (Lamblin ym. 2005). In 
our study we found that participants with high HGF-levels had more cardiovascular disease. HGF 
levels are elevated in various diseases (Funakoshi ja Nakamura 2003), and in our study population, 
the prevalence of different diseases was high. We found that higher levels of HGF were associated 
with higher mortality. The higher serum levels of HGF in the deceased participants may have been 
caused by attempts to repair failures in organ systems. 
 
4.1 Limitations and strengths of the study 
 
One strength of the study is that both community-dwelling and institutionalised persons were 
included. We acknowledge that there are limitations to our study. Data was missing for several 
variables, the loss of participants was reasonably high, and the relatively small population did not 
allow adjusted stratified analyses in different clinical subgroups. The small sample size and the lack 
of blind replication data might limit the ability of our data to decidedly indicate the studied markers 
as definitive predictors of mortality. 
 
4.2 Conclusions 
 
We found that elevated concentrations of HGF and VCAM-1 were strongly associated with higher 
mortality among nonagenarians. High levels of sFas seemed to slightly amplify the association of 
VCAM-1 and mortality. Moreover, the combination of simultaneously elevated concentrations of all 
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three markers predicted the risk of death in nonagenarians. Especially HGF and VCAM-1 seem to be 
independent prognostic markers, and their possible clinical uses should be studied further. 
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